To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
Our integrated approach ensures precise, timely and accurate results
Storage requirements and packaging also impact glutathione supplement quality
Therefore, while we are finalizing revisions to 180.50 effective beginning January 1, 2026, we will delay enforcement of those specific new requirements at 180.50 until April 1, 2026